Precigen, Inc. $PGEN Shares Purchased by Voya Investment Management LLC

Voya Investment Management LLC increased its holdings in shares of Precigen, Inc. (NASDAQ:PGEN) by 142.9% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 36,771 shares of the biotechnology company’s stock after purchasing an additional 21,633 shares during the period. Voya Investment Management LLC’s holdings in Precigen were worth $55,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Inspire Investing LLC purchased a new position in Precigen during the 1st quarter worth $350,000. MetLife Investment Management LLC purchased a new position in Precigen during the 1st quarter worth $124,000. Adage Capital Partners GP L.L.C. raised its position in Precigen by 3.8% during the 1st quarter. Adage Capital Partners GP L.L.C. now owns 11,276,000 shares of the biotechnology company’s stock worth $16,801,000 after buying an additional 410,595 shares during the last quarter. Nuveen LLC purchased a new position in Precigen during the 1st quarter worth $275,000. Finally, Parkman Healthcare Partners LLC purchased a new position in Precigen during the 1st quarter worth $4,755,000. Hedge funds and other institutional investors own 33.51% of the company’s stock.

Precigen Trading Up 1.5%

Shares of NASDAQ PGEN opened at $3.34 on Thursday. The stock has a market cap of $995.22 million, a price-to-earnings ratio of -7.95 and a beta of 1.61. Precigen, Inc. has a 52 week low of $0.65 and a 52 week high of $5.22. The company’s 50-day moving average price is $3.21 and its 200 day moving average price is $2.10.

Precigen (NASDAQ:PGEN) last issued its quarterly earnings data on Tuesday, August 12th. The biotechnology company reported ($0.11) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.03. The firm had revenue of $0.86 million for the quarter, compared to analysts’ expectations of $0.67 million. Precigen had a negative net margin of 2,868.66% and a negative return on equity of 842.83%. As a group, research analysts expect that Precigen, Inc. will post -0.32 earnings per share for the current year.

Insider Activity

In other news, Director Nancy H. Agee purchased 15,000 shares of the stock in a transaction dated Thursday, September 4th. The stock was acquired at an average cost of $4.60 per share, for a total transaction of $69,000.00. Following the completion of the acquisition, the director directly owned 217,841 shares in the company, valued at $1,002,068.60. This represents a 7.39% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Randal J. Kirk sold 1,809,667 shares of Precigen stock in a transaction dated Tuesday, September 30th. The stock was sold at an average price of $3.41, for a total transaction of $6,170,964.47. Following the sale, the director owned 14,597,161 shares of the company’s stock, valued at approximately $49,776,319.01. This trade represents a 11.03% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have acquired 54,221 shares of company stock valued at $214,467 and have sold 6,984,279 shares valued at $25,428,688. 47.10% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of brokerages have commented on PGEN. JMP Securities upped their price objective on shares of Precigen from $6.00 to $8.00 and gave the stock a “market outperform” rating in a research report on Tuesday, August 19th. Citigroup restated an “outperform” rating on shares of Precigen in a research report on Tuesday, August 19th. Wall Street Zen upgraded shares of Precigen from a “sell” rating to a “hold” rating in a research report on Saturday, July 12th. JPMorgan Chase & Co. upgraded shares of Precigen from an “underweight” rating to a “neutral” rating in a report on Friday, August 15th. Finally, HC Wainwright reiterated a “buy” rating and issued a $8.50 price target on shares of Precigen in a report on Tuesday, August 19th. Four investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $8.25.

Precigen Company Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.